Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)
Sponsor: Instituto Sistemas Complejos de Ingeniería
Summary
The Nirse-CL study is a collaborative effort between the Ministry of Health of Chile, Instituto Sistemas Complejos de Ingeniería (ISCI), and the Faculty of Medicine of the University of Chile. The primary aim is to determine the effectiveness of the monoclonal antibody nirsevimab in preventing RSV infection in infants based on the integrated analysis of several national databases before, during, and after the implementation of a universal immunization program. The impact of the program on RSV-related health outcomes will also be determined.
Official title: Effectiveness And Impact of Nirsevimab In A Nationwide Immunization Program During The 2024 Winter Campaign In Chile (Nirse-CL)
Key Details
Gender
All
Age Range
Any - 4 Years
Study Type
OBSERVATIONAL
Enrollment
160000
Start Date
2024-04-01
Completion Date
2024-10-01
Last Updated
2024-07-22
Healthy Volunteers
No
Conditions
Interventions
Nirsevimab
Nirsevimab will be administered in a single dose at birth for newborn cohort and at the beginning of the campaign for the other cohorts under study
Locations (1)
ISCI
Santiago, Chile